Innovative Medicines Innitiative (IMI)

The Innovative Medicines Initiative Joint Undertaking (IMI Joint Undertaking) supports collaborative research to improve the entire development process and make it more efficient, accelerating patients' access to better and safer medicines. Its function is none other than to promote the development of medicines, facilitating open collaboration in research.


Calls are published regularly on the innitiative's website.


Council Regulation 557/2014 of 6 May 2014 establishing the Innovative Medicines Initiative 2 Joint Undertaking |  DOUE L 169/54 de 7.6.2014

General information

Tagged as:

You may also be interested

Horizon Europe. Tools and technologies for a healthy society 

Horizon Europe. Research and Innovation Actions. Tools and technologies for a healthy society (Single stage - 2023): Clinical trials of combined Advanced Therapy Medicinal Products (ATMPs). HORIZON-HLTH-2023-TOOL-05-01 Integrated, multi-scale computational models of patient patho-physiology (‘virtual twins’) for personalised disease management. HORIZON-HLTH-2023-TOOL-05-03 Better integration and use of health-related real-world and research data, including genomics, for improved […]
W3 Funding & tender opportunities, 12.01.2023

Horizon Europa. A competitive health-related industry 

Horizon Europe. Coordination and Support Actions. A competitive health-related industry (Single stage - 2023): Supporting the uptake of innovative Health Technology Assessment (HTA) methodology and advancing HTA expertise across EU. HORIZON-HLTH-2023-IND-06-01 Expanding the European Electronic Health Record exchange Format to improve interoperability within the European Health Data Space. HORIZON-HLTH-2023-IND-06-02 Modelling and simulation to address regulatory […]
W3 Funding & tender opportunities, 12.01.2023